MOTS-c: The Mitochondrial-Derived Compound Reshaping Metabolic Research
PeptidexWhat is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a small bioactive compound encoded within the mitochondrial genome โ specifically within the 12S ribosomal RNA gene. It consists of 16 amino acids with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg and has a molecular weight of approximately 2,174 Da.
First identified and characterised by researchers at the University of Southern California in 2015, MOTS-c was a landmark discovery in the field of mitochondrial biology. For decades, the mitochondrial genome was thought to encode only 13 proteins, all components of the oxidative phosphorylation machinery. The identification of MOTS-c demonstrated that the mitochondrial genome also encodes small open reading frames capable of producing bioactive compounds โ a class now collectively referred to as mitochondrial-derived compounds (MDPs).
For research use only. Not intended for human or veterinary use.
Molecular Characteristics
MOTS-c is encoded within the 12S rRNA gene of the mitochondrial genome, a region previously considered non-coding in terms of protein output. The compound is produced in mitochondria but can translocate to the cytoplasm and nucleus, where it exerts regulatory effects on gene expression and metabolic signalling.
The compound is typically supplied as a lyophilised white powder and is soluble in aqueous solutions. Its small size and stability make it amenable to experimental administration via multiple routes in preclinical models, including subcutaneous and intraperitoneal injection.
The Folate-AICAR-AMPK Signalling Axis
The primary mechanism through which MOTS-c exerts its metabolic effects involves the folate cycle and the AMP-activated protein kinase (AMPK) pathway. Research published in Cell Metabolism (Lee et al., 2015) demonstrated that MOTS-c targets skeletal muscle and regulates glucose metabolism through the following sequence:
- MOTS-c inhibits the folate cycle and de novo purine biosynthesis in the cytoplasm.
- This inhibition leads to the accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a naturally occurring AMPK activator.
- Elevated AICAR levels activate AMPK, a master regulator of cellular energy homeostasis.
- AMPK activation enhances glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
This pathway explains many of the metabolic effects observed in preclinical MOTS-c studies, particularly those relating to insulin sensitivity and energy expenditure. A 2023 review in Molecular Medicine (Wan et al.) provided a comprehensive summary of this mechanism and its downstream consequences across multiple tissue types.
Metabolic Research Findings
Insulin Sensitivity and Glucose Metabolism
The original 2015 characterisation study demonstrated that MOTS-c administration in mice fed a high-fat diet significantly improved insulin sensitivity and reduced weight gain compared to controls. Skeletal muscle was identified as the primary target tissue, with MOTS-c increasing glucose transporter expression and enhancing insulin-stimulated glucose uptake.
A 2023 study published in Diabetes & Metabolism Journal examined MOTS-c in the context of type 2 diabetes, finding that circulating MOTS-c levels were inversely correlated with markers of insulin resistance in human subjects. The authors proposed that MOTS-c may function as an endogenous metabolic regulator that declines with age and metabolic dysfunction.
More recently, a 2025 study in Experimental and Molecular Medicine (Nature portfolio) investigated MOTS-c's role in pancreatic islet function, demonstrating that the compound helped prevent beta-cell senescence โ a process implicated in the progressive decline of insulin secretion in type 2 diabetes.
Obesity and Adipose Tissue
Beyond skeletal muscle, MOTS-c has been shown to influence adipose tissue biology. Research has demonstrated that MOTS-c promotes the browning of white adipose tissue โ a process that increases thermogenic capacity and energy expenditure. This effect is mediated in part through AMPK activation and the upregulation of uncoupling protein 1 (UCP1) in adipocytes.
A 2023 review in Frontiers in Physiology noted that MOTS-c's effects on adipose tissue, combined with its actions in skeletal muscle, position it as a candidate for investigation in models of obesity and metabolic syndrome.
Exercise and Physical Performance Research
One of the most compelling areas of MOTS-c research concerns its relationship with physical exercise. A landmark 2021 study published in Nature Communications (Reynolds et al.) established that MOTS-c is an exercise-induced compound โ circulating levels increase in response to physical activity in both mice and humans.
The same study demonstrated that MOTS-c administration in aged mice (equivalent to approximately 70 years in humans) significantly enhanced physical capacity, grip strength, and exercise endurance. Treated animals showed improvements comparable to those seen in younger, untreated controls. The researchers proposed that the age-related decline in exercise-induced MOTS-c may contribute to the progressive loss of physical function observed in ageing.
A 2024 study in iScience (Kumagai et al.) identified casein kinase 2 (CK2) as a direct molecular target of MOTS-c in skeletal muscle, providing mechanistic insight into how the compound modulates muscle function at the cellular level. This finding opened new avenues for understanding the compound's role in muscle physiology and age-related sarcopenia.
Ageing and Longevity Research
MOTS-c has attracted significant interest in the field of geroscience โ the study of the biological mechanisms of ageing. Several lines of evidence support a role for MOTS-c in the regulation of lifespan and healthspan:
Circulating levels decline with age. Multiple studies have documented that plasma MOTS-c concentrations decrease progressively with advancing age in both animal models and human cohorts. This decline correlates with the emergence of age-associated metabolic dysfunction.
Nuclear translocation under stress. A 2019 study demonstrated that MOTS-c translocates from the mitochondria to the nucleus in response to metabolic stress, where it directly regulates nuclear gene expression. This mitochondrial-to-nuclear signalling capacity suggests a role for MOTS-c in coordinating cellular stress responses โ a function central to healthy ageing.
Centenarian studies. Research examining genetic variants in the MOTS-c encoding region of the mitochondrial genome found that certain variants associated with higher MOTS-c activity were enriched in long-lived individuals, including centenarians. While these findings are preliminary, they are consistent with a role for MOTS-c in longevity regulation.
Anti-Inflammatory Properties
MOTS-c has demonstrated anti-inflammatory activity across multiple experimental models. A 2023 study published in PMC found that MOTS-c administration significantly reduced levels of pro-inflammatory cytokines โ including TNF-ฮฑ, IL-1ฮฒ, and IL-6 โ while increasing anti-inflammatory mediators such as IL-10.
These effects have been observed in models of metabolic inflammation, neuropathic pain, and systemic inflammatory conditions. A 2024 study in Life Sciences examined MOTS-c in a model of spared nerve injury-induced neuropathic pain, finding that the compound ameliorated pain behaviours through anti-inflammatory and neuroprotective mechanisms.
Bone Metabolism Research
An emerging area of MOTS-c research concerns its effects on bone biology. A 2023 review in Frontiers in Physiology (Yi et al.) summarised evidence that MOTS-c promotes osteoblast proliferation, differentiation, and mineralisation โ the processes responsible for new bone formation. Simultaneously, the compound was found to inhibit osteoclast activity, the cell type responsible for bone resorption.
This dual action on bone turnover has led researchers to propose MOTS-c as a candidate for investigation in models of osteoporosis, particularly postmenopausal bone loss, where the balance between formation and resorption is disrupted.
Cardiovascular Research
MOTS-c has been investigated in several cardiovascular contexts. A 2025 review in Life Sciences examined the relationship between MOTS-c and type 2 diabetes-associated cardiac complications, noting that the compound's metabolic and anti-inflammatory properties may be relevant to diabetic cardiomyopathy research.
Preclinical studies have also examined MOTS-c in models of ischaemia-reperfusion injury, where its ability to reduce oxidative stress and inflammation may be relevant to myocardial protection research.
MOTS-c and the Mitochondrial-Derived Compound Family
MOTS-c belongs to a broader family of mitochondrial-derived compounds (MDPs) that includes humanin and the SHLP (small humanin-like compound) family. These compounds share several characteristics: they are encoded within the mitochondrial genome, they are released in response to cellular stress, and they exert cytoprotective and metabolic effects.
The discovery of this compound family has fundamentally altered understanding of mitochondrial biology, establishing the mitochondrion not merely as the cell's energy factory but as an endocrine organ capable of producing signalling molecules that coordinate systemic physiology.
| Compound | Gene Region | Primary Research Areas |
|---|---|---|
| MOTS-c | 12S rRNA | Metabolic regulation, exercise, ageing |
| Humanin | 16S rRNA | Neuroprotection, apoptosis, insulin sensitivity |
| SHLP2 | 16S rRNA | Mitochondrial biogenesis, anti-apoptotic |
| SHLP3 | 16S rRNA | Metabolic regulation |
| SHLP6 | 16S rRNA | Pro-apoptotic (cancer research) |
Current Research Status
MOTS-c remains an active area of preclinical investigation. As of 2025, no clinical trials of exogenous MOTS-c have been completed in humans, and the compound has not been approved for therapeutic use in any jurisdiction. All available data derives from cell culture experiments and animal models.
The compound is available for research purposes and is used in laboratory settings to investigate the mechanisms described above. Researchers working with MOTS-c should consult current literature and institutional guidelines for appropriate experimental protocols.
Summary
MOTS-c is a mitochondrial-derived compound with a distinctive mechanism of action centred on the folate-AICAR-AMPK signalling axis. Preclinical research has identified potential roles in metabolic regulation, exercise physiology, ageing biology, inflammation, bone metabolism, and cardiovascular research. Its discovery has contributed to a broader reconceptualisation of the mitochondrial genome as a source of bioactive signalling molecules.
Research into MOTS-c and related mitochondrial-derived compounds continues to expand, with particular interest in understanding how the age-related decline in circulating MOTS-c levels contributes to metabolic dysfunction and the biology of ageing.
This article is intended for informational and educational purposes only. MOTS-c is available for research use only and is not approved for human or veterinary therapeutic use. All referenced studies are preclinical unless otherwise stated.
